Pyrrolo{8 1,2,3-de{9 quinoxalin-2(3H)-ones and related compounds

ABSTRACT

This invention concerns pyrrolo(1,2,3-de)quinoxalin-2(3H)-ones and related compounds which are pharmacologically active as central nervous system depressants.

United States Patent Sellstedt et al. July 1, 1975 [5 PYRROLO[1,2,3-de]QUINOXALIN- [51] Int. Cl C07d 87/42 2(3H)-ONES AND RELATED COMPOUNDS [58] Field of Search... 260/256.4 F, 268 TR, 250 Q, [75] Inventors: John H. Sellstedt, King of Prussia; 26O/247'2 A Milton Wolf, West Chester, both of Pa Primary ExammerDonald G. Daus Assistant Examiner.lose Tovar Asslgneei American Home Products Attorney, Agent, or Firm-Joseph Martin Weigman Corporation, New York, NY.

[22] Filed: Jan. 27, 1972 [21] App]. No.: 221,416 [57] ABSTRACT Related s Application Data This invention concerns pyrrolo[l,2,3-de]quinoxalin- [63] Continuation of Ser. No. 831 723', June 9 1969, 26mm and related compounds which are Phar' abandonedmacologically active as central nervous system depressants.

[52] US. Cl....260/247.2 A; 260/250 Q; 260/268 TR;

28 Claims, No Drawings PYRROLOO,2,3-DE)QUINOXALIN-2(SID-ONES AND RELATED COMPOUNDS This application is a continuation of application Ser. No. 831,723 filed June 9. 1969, and now abandoned.

This invention relates to new and novel quinoxalines. More particularly it relates to pyrrolol 1 ,2.3-de]quinox alin-2 (3H)-ones and related compounds which in standard accepted biological tests have demonstrated use fulness as central nervous system depressants.

The new and novel compounds of the present invention are exemplified by those having the formula:

wherein R and R are selected from the group consisting of hydrogen, nitro, amino, carboxy, cyano, carba myl, sulfamyl, trifluoromethyl, halogen, lower alkyl, lower alkoxy, lower alkylthio, carb(lower)alkoxy, lower alkylsulfonyl, carboxy (lower)alkyl, lower alkanoylamino, di(lower)alkylamino, phenyl, halophenyl, lower alkylphenyl, lower alkoxyphenyl, phen(- lower) alkyl, phen(lower)alkoxy, morpholino, pyridyl, furyl, and naphthyl; R and R when taken separately are selected from the group consisting of hydrogen, cyano, carboxy, carbamyl, lower alkyl, hydroxy(lower)alkyl, carb(1ower)alkoxy, carb(1ower)alkoxy (1ower)alkyl, carboxy(lower)alkyl, di(lower)alky1amino(lower) alkyl, phenyl, hydroxyphenyl, lower alkylphenyl, lower alkoxyphenyl, halophenyl, phen(lower)alkyl, benzoxyphenyl, pyridyl, fury], and naphthyl; R and R when concatenated and taken together with the two carbon atoms to which they are attached complete a ring seg w R1 NO lected from the group consisting of l-(lower)alkyl- 60 {12 Reduction (2) Cyclization,

)alkyl[ N-(lowerjalkyl-N'-(lower)alkanoylamino(lower)alkyl, aziridinyl(lower)alkyl, azetidinyl(lower )alkyl, azo1idinyl(1ower)alkyl. azinyl(lower)alkyl, azepinyl(- lower)alkyl, l-(lower)alkylpiperazinyl(lower)alkyl, pheny1piperazinyl(lower)alkyl. halophenylpiperazinyl(lower)alkyl and lphen(lower)alkylpiperazinyl(lower)alkyl. As employed herein the terms lower alkyl", lower alkoxy, lower alkanoyl and the like are meant to include both branched and straight chain hydrocarbon groups having from one to about seven carbon atoms. The term halogen as used herein is meant to include chlorine, bromine, iodine and fluorine. Typical examples of these compounds are: 7,8,9,lO-tetrahydr0-8-methy1- 1H-pyrido[3',4:4,5]pyrrolo[1,2,3-dejquinoxalin-2- (3H)-one; 8,9-dihydro-1H,7H- benzo[3',4]cyclohepta[1,2':4,5]pyrrolo[1,2,3- de ]quinoxalin-2-( 3H )-one; 8,9, 10,1 1 -tetrahydrolH,7H-cyclohepta[4,5]pyrrolo 1.2,3-delquinoxalin- 2-(3Hl-one; 7,8,9,10.1 1,12-hexahydro-1H- cyclooctal 4,5-pyrrolo[ l,2,3-de]quinoxalin- 2( 3H )-one; 8-tert-butyl-7,8,9, IO-tetrahydro-l H- pyrazino[3,2,1-jk]carbazo|-2(3H) one; 2,3-dihydro-2- oxo-5-phenyl-1H-pyrrolo['1,2,3-delquinozaline-6- acetic acid; 8,9, 10,1 l-tetrahydro-3-methyl-lH,7H cyclohepta[4,5 ]pyrrolo[ l ,2,3-de]quinoxalin- 2(3H)-one; 3-(2-dimethylaminoethyl)-8,9,10,l1 -tetrahydro-l H,7H-cyclohepta[4,5 ]pyrrolo[ 1 .2,3-de]- quinoxalin-2(3H)-one; 2,3,8,9,l0,1 1-hexahydro-2- oxo-lH,7H-cyclohepta[4,5]pyrrolo[1,2,3-de]quinoxaline-3-acetonitrile; 8,9,10,1 1-tetrahydro-3-phenethyl- 1H,7H-cyclohepta[4,5]pyrrolo[1,2,3-de]quinoxalin- 2( 3H )-one; 6-methyll Z-dimethylaminoethyl )5- phenyll l-l-pyrrol0[ l ,2,3-de]quinoxalin-2( 3H )-one; and 1-( 3-dimethylaminopropyl )-5-methyl-6-phenyl- 1H-pyrrolo[ l,2,3de]quinoxalin-2-( 3H )-one.

The new and novel compounds of the present invention may be prepared by the process which ix exemplified by the following reaction scheme:

Alkylation, 3 X

wherein R,, R. R R and R; are defined as above and X is a halogen. The position numbers for the structural formulae of the compounds of the present invention are as follows. v

The reduction-cyclization reaction is effected by contacting a 4-nitroso-3,4-dihydroquinoxalin-2-(1H)-one (I) with zinc dust in acetic acid for about one-half hour at about ambient temperatures. Thereafter, the reduced mixture is contacted with an approximate ketone (II) at about reflux temperatures for a period of up to about thirty minutes to afford an appropriate 1- unsubstituted product (III). Preferably this reaction is conducted in glacial acetic acid. When the reductioncyclization reaction is complete, the l-unsubstituted product (III) is separated by conventional recovery procedures e.g. filter the reaction mixture, wash the cake with acetic acid and a liquid alkanol, and crystallize the l-unsubstituted product (III) from a suitable solvent, such as, dimethylformamide or dimethylacetamide.

The alkylation reaction is effected by admixing the above-prepared l-unsubstituted product (III) with hexane washed fifty percent sodium hydride, in an anhydrous, reaction-inert solvent, e.g. dimethylformamide. To this mixture, there is added a solution of an appropriate halide (IV) in an anhydrous, reaction-inert solvent, e.g. dimethylformamide at a temperature range from about 70C. to about 90C. for a period of up to about two hours. When the alkylation is complete, the resulting l-substituted product (V) is recovered by standard techniques. For example, the solvent is evaporated to afford a residue which is purified and then crystallized from a suitable solvent, e.g. an alkanol.

The 4-nitroso-3.4-dihydroquinoxalin-2-( l-H)-ones (I) employed as starting materials in the abovedescribed process are prepared by the procedure of Perkin, W. H. and Riley, G. C. in J. Chem. Soc., 2399 (1923). The ketones (II) and halides (IV) employed in these reactions are commerciallyavailable or are easily prepared by processes well known in the chemical art.

The new and novel 1-unsubstituted (III) and 1- substituted (V) products of this invention possess valuable pharmacological activity. In particular, these compounds in standard pharmacological procedures demonstrate nervous system activity and are useful as depressants. Because of this property they are of particu-. lar importance in producing a calming effect in animals.

In the pharmacological evaluation of the central nervous system depressant compounds of this invention the in vivo effects of the compounds of this invention are tested as follows:

The compound is administered orally and intraperitoneally to three mice (14 to 24 grams) at each of the following doses: 400, 127, 40 and 12.7 mg./kg. The animals are watched for a minimum of two hours during which time signs of general stimulation (i.e., increased spontaneous motor activity, hyperactivity on tactile stimulation, twitching), general depression (i.e., decreased spontaneous motor activity, decreased respiration) and autonomic activity (i.e., miosis, mydriasis', di arrhea) are noted. The animals are tested for changes in reflexes (i.e., flexor, extenso r) and are rated by use of a pole climb and inclined screen for the presencce of sedation-ataxia. The Eddy Hot-Plate Method [Nathan B. Eddy and Dorothy IJeimbach, I J. Pharmacol. Exper. Therap. 107, 385 (1953)] is used to test for analgesia. The experiment is terminated by subjecting each animal to a maximal electroshock to test for anti-convulsant activity. I

The compounds of this invention in the above test procedure induce decreased motor activity and decreased respiration when administered at a dosage range of 12.7 to 400 mg./kg. There were no deaths in the test animals at the highestdose used, 400 mgjkg.

pyrrolol 1 ,2,3-de]quinoxalin-2( 3H )-one; I-( 2- diethylaminoethyl)-6-ethyl-5-phenyl-1H- pyrrolol 1 ,2,3-de]quinoxalin-2( 3H)-one; 6-ethyl-5- phenyl-1-[3-( l-pyrrolidinyl)-propy1]-1H- pyrro1o[ l,2,3-de]quinoxa1in-2(3H )-one; I-( 3- dimethylaminopropyl )-5-(p-methoxypheny1)-6-methyl-1H-pyrrolo[1,2,3 -de ]quinoxalin-2( 3H )-one; 5-( pbenzyloxyphenyl)-1-(3-dirnethylaminopropyl)-6- methyl- 1 H-pyrrolol 1 ,2.3-de ]quinoxalin-2( 3H )-onei I 1-(3-dimethylaminopropyl)-5-(p-hydroxyphenyl)-6- methyl-1 H-pyrrolol 1 ,2,3-de]quinoxalin-2( 3H )-on e',; 6-methyl-1-(Z-diinethylaminoethyl)-5-phenyl-l H- pyrrolol1.2,3-de]quinoxalin-2(3H )-one; 3,- 2- dimethylaminoethyl)-7,8,9,10,1 1,12,-hex,ahydr0-1H- .cyc1oocta[4,5]pyrrolo[1,2,3-de]quinoxalin 2( 31-1 )-one'. S-benzyl-1-(2-dimethylaminoethyl)-6- phenyll l-lpyrrolo[ l ,2,3-de]quinoxalin2( 3H )one; and l-(Z-dimethylaminoethyl)-6-ethyl-5-phenyl1H pyrrolol1,2,3-delquinoxalin-2(3l-l)-one. Still further, some of the l-substituted products (V) of the present invention have also demonstrated immunosuppressive activity by their ability to inhibit experimentally induced allergic encephalomyelitis in rate when administered at an intraperitoneal dosage range of about 100 to about 200 mg./kilo of body weight. This immunosuppressive activity was tested by procedures of Brandriss, M. W. Science 140:186, 1963 and Levine et al. Proc. Soc. 1 14:220, 1963. The compounds which have demonstrated this activity are: 1-( 3-dimethylaminopropyl)- 6-ethyl-5-phenyll H-pyrrolo[ 1 ,2,3-de]quinoxalin- 2( 311 )-one; l-( Z-dimethylaminoethyl )-6-ethyl-5- phenyl-1Hpyrrolo[ l,2.3 de]quinoxalin-2( 3H )-one;'

and 1-(3-dimethylaminopropyl)-5-(p-hydroxyphenyl)- 6-methyll H-pyrrolo[ l ,2,3-de]quinoxalin-2( 3H)-one.

When the compounds (Ill and v) of this invention are employed as central nervous system depressants they may be administered to warm-blooded animals, e.g. mice, rats, rabbits, dogs, cats, monkeys, etc. alone or in combination with pharmacologically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard biological practice. For example, they may be administered orally in the solid form containing such excipients as starch, milk sugar, certain types of clay and so forth. They may also be administered orally in the form of solutions or they may be injected parenterally. For parenteral administration they may be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.

The dosage of the present central nervous system depressants will vary with the form of administration and the particular compound chosen. Furthermore, it will vary with the particular subject under treatment. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In general, the compounds of this invention are most desirably administered at a concentration level that will generally afford effective results without causing any harmful or deleterious side effects.

EXAMPLE 1 4-Nitroso-3,4-dihydroquinoxalin-2( ll-l)-one g.. 0.113 mole) is stirred in glacial acetic acid (300 ml). and zinc dust (40 g.) is added in portions while keeping the temperature below C. When all of the zinc has been added the mixture is stirred an additional 20 minutes. Then the reduction mixture is filtered into a oneliter flask containing propiophenone (15.2 g., 0.113 mole), and the zinc cake washed with acetic acid 100 ml.) before it dries. The solution is stirred and slowly heated to reflux until crystals form. If crystals form below reflux, the mixture is refluxed for 10 minutes, cooled to 20C. in ice, filtered and washed with acetic acid then ethanol, giving light yellow crystals 1 1.2 g., 36%), m.p. 285-288C. (uncorr.) which crystallized from dimethylformamide, give white crystals of 6- methyl-S-phenyl-lH-pyrrolo[1,2,3-de]quinoxalin- 2(3H)-one (10.7 g., percent), m.p. 288-290C.

(uncorr.). I

Anal: Calcd for C, H N O: C, 77.84; H, 5.38; N. 10.68. Found: C, 77.92; H, 5.31; N, 10.75.

ucts are obtained:

KETONE PRODUCT N-methyl-4-piperidone 1 -benzosuhcrone cycloheptanone cyclooctanone 4-t-butylcyclohcxanone 3-benzoylpropionic acid cyclopentanonc a-tetralone butyrophenone cyclododecanone phenyl-Z-propanonc ethylacetoacetate benzoylacetonitrile 4-hydroxy-4'-methoxybutyrophenone 4-h \'droxy-4 methoxy butyrophcnone Z-pentanone valerophenone m-chloropropiophenone o-chloropropiophenonc levulinic acid p-benzyloxypropiophanone 7.8.9,10-tetrahydro-l'l-methyl 1N-pyridol3'.4':4,5lpyrrolo l 1.2.3-de ]quinoxalin2(3H)-onc, m.p. 265-267.5C.. (19% yield). 8.9-dihydrol H.7H-benzo[ 3 14' I cycloheptal 1 '.2':4,5 Ipyrrolo 1.2.3-de Iquinoxalin-Zl 3H )one m.p. 295297C., (37% yield). 8.9.10.1 l-tetrah ydro-IHJH- cycloheptal 4.5 lpyrrolol 1.2.3-de] quinoxalin-2(3H)-one. m.p. 279-282C.. (44% yield). 7.8.9.10.l 1.12-hCXflhydlO-1FL cyc1oocta[4.5 lpyrrolol 1.2.3-de] quinoxalin-2(3H)-one, m.p. 224-227C.. (31% yield). 8-t-hutyl-7.8.9.10-tetrahydro -1H-pyrazino[3,2.l-jk Icerbozol Z(3H)-one, m.p. 279282C.. (38% yield). 2,3-dihydro-2-oxo-5-phenyl- 1 H pyrrolol 1.2.3-de lquinoxoline -o acctic acid. m.p. INN-303C. (decomp.). 16% yield).

8 ,9,-dihydro- 1 H.7H-cyclopenta [4,5 lpyrrolol l.2.3-de lquinoxulin -2(3H)-one, mp. 283-285C.. (38% yield).

7.8-dihydro-l H-benzel a lpyrazino [3,2, 1 -jK ]carbazol2( 3H )-one, m.p. 309-31 1C.. (2371 yield). fi-ethyl-S-phenyl- 1 H pyrrolo l l,2,3-de]quinoxalin 2( 3H )-one. m.p. 245-246C.. (547: yield). .8.9.l0.ll.l2.13 14.15,16- dccahydro- 1 H cyclododecal 4.5 pyrrolol 1.2.3-de1quinoxalin -2(3H)-ene. m.p. 247249C.. (56% yield) 5-methyl-6-phenyL 1 H-pyrrolo l.2.3-de]quinoxa1in-2(3H)-one. m.p. 282-284C.. (51% yield). 2,3-dihydro-5-methyl-Z-oxo-1X- pyrrolol 1.2.3 de lquinoxaline fi carhoxylie acid. ethyl ester.

m.p. 266.5-267.5C.. 15% yield).

2.3-dihydro-2-oxo-5-phenyl 1H- pyrrolol l.2 3-delquinoxalino-ficarbonitrile. m.p. 312313C.. (36% yield). 6-(Z-hydroxyethyl)-5-(p-methoxyphenyl 1 H-pyrrolol 1.2.3-dc quinoxalin-2( 3X )-one, acetate, m.p. 199-20lC., (6% yield).

6-( Z-hydroxyethyl )-5-( n-niethoxyphenyl)-lH-pyrro1o| 1.2.3-de lquinoxalin-Z( 3N J-one. mp. 23 1- 233C. (97: yield). 6ethyl-5-methy1-lH-pyrrolo 1.2.3de ]quinoxalin-2( 3H )-0ne. m.p. 217-219C.. (38% yield). 5phenyl-6-propyl- 1 H-pyrrolo l 1.2,3-de lquinoxulin-2( 3H )-one m.p. Z3()-230.5C.. (48% yield).

5-( m-chlorophenyl )-6-methyl- 1 H- pyrrolol1.2.3-de1quinoxalin- 2(3H)ene m.p. 273276C., yield). S-(o-ehlorophenyl)-6-methyl-1H- pyrrolol 1,2.3-de |quinoxalin 2(3Hj-one, nI.pv 219-222C.. (28% yield). 2.3-dihydro-5-methyl-2-oxo-1H- pyrrolol 1.2.3-do ]quinoxaline-6- acetic acid. m.p. 286-287C, (decomp) (28% yield). S-benzyloxyphenyl )-6-methyl -H-pyrrolo[ 1.2,3-delquinoxalin -2,3H)-ene, m.p. 27()273C.. (52% yield).

-Continued KETONE PRODUCT p-methoxypropiophenone p-chloropropiophenonc EXAMPLE Ill 4-Nitroso-3,4-dihydroquinoxalin-2( lH )-one (0.5 65 mole) is stirred in glacial acetic acid (1500 ml.) and zinc dust (200 g.) is added in portions while keeping the temperature below 25C. When all of the zinc has been added, the mixture is stirred an additional half hour. Then the reaction mixture is filtered into a five liter flask containing l,3-diphenylpropanone 0.565 mole), and the zinc cake washed with acetic acid (500 ml.). The reaction solution is stirred and slowly heated to reflux until crystals form. If crystals form before reflux, the mixture is refluxed for l minutes, cooled in ice, filtered and washed with acetic acid then ethanol, giving crystals of -benzyl-6-phenyl-lH-pyrrolo[1,2,3- de]quinoxalin-2(3H)-one. m.p. 240242C. (55 percent yield).

Anal. Calcd for c u m o; C, 81.63; H, 5.36; N, 8.28. Found: C, 81.46; H, 5.34; N, 8.27.

EXAMPLE IV When the procedure of Examples 1-1 is repeated to react a 4-nitros0-3,4-dihydroquinoxalin-2(lH)-one with an appropriate ketone. there is afforded compounds of the following formula:

wherein R., R R and R are defined as follows:

R1 R2 il R4 hydrogen S-cyano p-tolyl propyl 8-chloro 9-chloro carboxy p-bromophenyl 8-trifluorohydrogen hydrogen carbomethoxy methyl 7-ethoxy 8-amino carhamyl p-hydroxyphenyl 9-bromo 8-carboxy p-ethylphenyl hydrogen S-ethyl hydrogen hydrogen p-methoxyphenyl 8-fluoro 9-sulfamyl hydrogen butyryl 8-nitro Q-phenyl p-iodophenyl hydrogen 8-carbamyl 9-methylthio hydrogen valeryl 7-butyl hydrogen hydrogen carbethoxy 8'ethylthio 9-iodo phenpropyl hydrogen 8-methoxy Q-methoxy hydrogen dimcthylaminoeth 'l p-chlorophenyl hydrogen hydrogen hyd rogen X-morpholino hydrogen hydrogen Z-pyridyl 9-methylsulfonyl 9-propoxy hydrogen Z-naphthyl hydrogen 9-acetamido hydrogen cyano 8'ethylsulfonyl 9-acetyl hydrogen m-fluorophenyl 7-carbomethoxy X-benzyl hydrogen naphthyl S-dimethylamino hydrogen hydrogen 2-furyl 8-pyridyl 9-butylthio dimethylaminohydrogen ropyl hydrogen 9-benzyloxy liydrogen hydrogen B-carbethoxy 9;lp-brlomop-hutoxyphcnyl hydrogen P y 7-propionyl hydrogen hydrogen phcnethyl 8-phen ethyl hydrogen hydrogen hydrogen 8-propionamido hydrogen hydrogen carbpropoxy EXAMPLE 4-Nitroso-3,4-dihydroquinoxalin-2( l H)-on e (0.226 mole) is stirred in glacial acetic acid (600 ml.) and zinc dust g.) is added in portions while keeping the temperature below 25C. When. all of the zinc has been added, the mixture is stirred an additional half hour. Then the reduction mixture is, filtered into a one liter flask containing N-ethyl-4-piper idone (0.226 mole), and the zinc cake washed with acetic acid (200 ml.). The reaction mixture is stirred and slowly heated to reflux for 10 minutes. Thereafter, the mixture is cooled in ice, filtered and washed with acetic acid then methanol, to afford 8-ethyl-7,8.9, lO-tetrahydrol H- pyrido[3',4':4,5] pyrrolol l ,2,3-de]quinoxalin- 2( 3H)-one.

Similarly, when the following ketones are reacted with an appropriate 4-nitros o-3.4-dihydroquinoxalin- 2( lH)-one, the followingproducts are afforded:

KETONE PRODUCT 7.8,9, lO-tetrahydrdS-propyl- H-pyridol 3".4':4.5 lpyrrolo l,2.3- de ]quinoxalin-2( 3H )-one. .89. l 0-tetrahydro-5 .8-dimethyl l-H-pyrido[ 3 .4 14.5 lpyrrolo l-methylpiperidonc 4-propylpiperidone EXAMPLE VI When the procedure of the prior Examples are repeated -to react a 4-nitroso-3,4-dihydroquinoxalin- 2( lH)-one with an appropriate ketone, the following 7 compounds are prepared:

'6-( 3-hydroxypropyl )-8-phenbutyll H-pyrrolo[ 1,2,3-

de]quinoxalin-2(3H)-one propionate;

8-benzyl-lH-pyrrolo[1,2,3-delquinoxalin- 2(3H)-one;

8-(2-furyl)-lH-pyrrolo[1,2,3-de1quinoxalin- 2(3H)-one;

9-diethylamino-1H-pyrrdlo[ l', 2,3-de]quinoxalin-- 2(3H)-one; I

8-'( Z-naphthyl )-l H-pyrrolo[ l',2,3-de]quinoxalin- 2(3H)-one;

7-(m-butylphenyl l H-pyrrolol l,2,3-de]quinoxalin- 2(3H)-one;

8-(p-methoxyphenyl l H-pyrrolo[ l,2,3-de]quinoxalin-2(3H)-one; v

8-( p-propoxyphenyl l H-pyrrolo[ l ,2;3-de ]quinoxalin-2(3H)-one;

8-phenethoxyl H-pyrrolo[ 1,2,3-de1quinoxalin- 2(3H)-one;

9-dipropylaminol H-pyrrolo[ 1 .2,3-de]quinoxalin- 2(3H)-one;

8-( o-iodophenyl)- l H-pyrrolo[ l ,2,3-de]quinoxalin- 2(3H)-on'e;'and

8-( N-methyl- N '-propylamino)-lH-pyrrolo[1,2,3-

de]quinoxalin-2(3H)-one.

I EXAMPLE Vll 6-Ethyl-5-phenyl-lH-pyrrolol1,2,3-de1quinoxalin- 2(3H)-one (8.3 g.,.0.03 mole) is added to a mixture of hexane washed 50 percent sodium hydride (l.52 g.,

0.0316 mole) in anhydrous dimethylformamide (50 ml.), and the mixture is stirred at room temperature until all the solids dissolve. A solution of 3- dimethylaminopropyl chloride (4.02 g., 0.033 mole) in anhydrous dimethylformamide (5 ml.) is added all at once, and stirred at 7090C. for one and a half hours. All of the solvent is removed under vacuum and the residue is dissolved in a mixture of methylene chloridewater. The water is extracted once more with methylene chloride, and the methylene chloride washed with water, saturated salt, and dried with sodium sulfate. Concentration under vacuum, gives a tan solid g.), m.p. 108C. (uncorr.). The solid is crystallized from absolute ethanol, giving white crystals of 6-ethyl-l-(3- dimethylaminopropyl)-5-phenyl-1 H-pyrrolo [1,2,3- de]quinoxalin-2(3H)-one (9.5 g., 88 percent yield), m.p, 114-1l6C. (uncorr.).

Anal. Calcd for C H N O: C, 76.42; H, 7.53; N. 11.63. Found: C, 76.36; H, 7.51; N, 11.70.

EXAMPLE VIII When the procedure of Example Vll'is repeated to react pyrrolo[ l ,2,3-de]quinoxalin-2( 3H)-ones with appropriate halide derivatives, the following compounds are afforded:

3(S-dimethylaminopropyl)-8,9, 10,1 l-tetrahydro- 1H,7ll-cyclohepta[4,5]pyrrolo[1,2,3-dejquinoxalin-2(3l-l)-one, m.p. 104-106C., 56 percent yield;

8,9,l0,1 l-tetrahydro-3-methyl-1l-l,7H-

cyclohepta[4,5]pyrrolo[1,2,3-deJquinoxalin- 2(3H)-one, m.p. 113-l15C., 100 percent yield;

3-(Z-dimethylaminoethyl)-8,9,10,1l-tetrahydro- 1H,7H-cyclohepta[4,5]pyrrolol l ,2,3-de]quinoxalin-2(3H)-one, m.p. 101.5-l03C., 49 percent yield;

2,3,8,9,10,l 1-hexahydro-2-oxo-1H,7H-

cyclohepta[4,5]pyrrolo[1,2,3-de]quinoxaline-3- acetonitrile, m.p. 239-241C., 67 percent yield;

8,9, 10,1 l-tetrahydro3-phenethyl-1H,7H-

cyclohepta[4,5]pyrrolo[ l,2,3-de]quinoxalin- 2(3H)-one, m.p. 163.5165C., 41 percent yield;

6-methyl-I-(Z-dimethylaminoethyl)-5-phenyllH- pyrrolo[1,2,3de]quinoxalin-2(3H)-one, m.p. 150152C., 68 percent yield;

l-( 3-dimethylaminopropyl)-5-methyl-6-phenyll H- pyrrolo[ l,2,3-de]quinoxalin-2(3H)-one, m.p. 140-142.5C., 84 percent yield;

3-(2-dimethylaminoethyl)-7,8,9.l0,l1,12

hexahydrol H-cycloocta[4,5 ]pyrrolo[ l,2,3-de]- quinoxalin-2(3H)-one, m.p. l 12114C., 64 percent yield;

3-(3-dimethylaminopropyl)-8,9-dihydro-1H,7H- cyclopenta[4,5 ]pyrrolo[ l ,2,3-de ]quinoxalin- 2(3H)-one, m.p. 102103C., 68 percent yield. 5-benzyl1-(Z-dimethylaminoethyl)-6.-phenyl-1H- pyrrolo[ l ,2,3-de]quinoxalin-2(3H)-one, 152l53C., 60 percent yield;

1 -(3-dimethylamino-2-methylpropy1 )-6-ethyl-5- phenyl-lH-pyrrolo[1,2,3-de]quinoxalin- 2(3H)-one, m.p. 121123C., 40 percent yield;

1-(3-dimethylamino-1-methylpropyl)-6-ethyl-5- phenyl-lH-pyrrolo[1,2,3-delquin0xalin- 2(3H)-one, m.p. 96.5-98C.. 17 percent yield;

1-(2-dimethylaminoethyl)-6-ethyl-5-phenyl-1H- pyrrolo[1,2,3-de]quinoxalin-2(3H)-one, l54l55.5C., 76 percent yield;

l-( 3-dimethylaminopropyl )-6-methyl-5-phenyll H- pyrrol0-[ l ,2,3-de]quinoxalin-2(3H)one, 127.5-129.5C., 80 percent yield; I

pyrrolo[ l ,2,3-de]quinoxalin-2( 3H )-one. m.p.

l60-l61.5C., 84 percent yield; 6-ethyl-1-(3-methylaminopr0pyl)-5-phenyl-l H- pyrrolo[1,2,3-de]quinoxalin-2(3H)-one, m.p.

2l2-214C., 30 percent yield; 6-ethyl-5-phenyl-l-[3-(1-pyrrolidinyl)propyl] -lH- pyrrolol 1 ,2,3-de]quinoxalin-2-( 3H )-one, m.p. 135-136C., 77 percent yield; l-(B-dimethylaminopropyl)-5-(p-methoxyphenyl)-6- methyl- 1 H-pyrrolol l ,2,3-de]quinoxalin 2(3H)-one, m.p. 169.517lC., 85 percent yield; S-(p-benzyloxyphenyl )-1-( 3-dimethylaminopropyl)- 6-methyl-lH-pyrrolol l,2,3-de]quinoxalin- 2(3H)-one, m.p. 138140C., 79 percent yield; 5 (m-chlorophenyl l 3-dimethylamino propyl )-6- mcthyl-lH-pyrrolol1,2,3-de]quinoxalin- 2(3H)-one, m.p. 107-'109C., 77 percent yield; 5-(p-chlorophenyl)-l-(3-dimethylaminopropyl)-6- methyl-lH-pyrrolo[1,2,3-delquinoxalin- 2(3H)-one, m.p. 186-188C., 71 percent yield; 1-(3-dimethylaminopropyl)-5-(p-hydroxyphenyl)-6- methyl-lH-pyrrolo[ 1,2,3-de]quinoxalin- 2(3H)-one, m.p. 172.5175.5C., 88 percent yield; l-(3-dimethylaminopropyl)-5-phenyl-1H- pyrrolo[1,2,3-de]quinoxalin-2(3H)-one, 13l-l32C., 14 percent yield; and 5-(o-chlorophenyl 1 3-dimethylaminopropyl )-6- methyl- 1 H-pyrrolo[ 1,2,3-de1quinoxalin- 2(3H)-one, m.p. l90.5-l92.5C., 61 yield.

percent EXAMPLE lX 7,8,9,10-Tetrahydro-8-methyl-1H- pyrido[3 ',4:4,5]pyrrolo[ 1,2,3-de1quinoxalin-2- (3H)-one (0.06 mole) is added to a mixture of hexane washed 50 percent sodium hydride (0.0632 mole) in anhydrous dimethylformamide (50 ml.), and the mixture is stirred at room temperature until all the solids dissolve. A solution of 3-dimethylaminopropyl chloride (0.066 mole) in anhydrous dimethylformamide (10 ml.) is added all at once, and stirred at 90C. for 2 hours. All of the solvent is removed under vacuum and the residue is dissolve in a mixture of methylene chloride-water. The water is extracted once more with methylene chloride, the methylene chloride washed 22. A compound as described in claim 1 which is: 5- (p-benxyloxyphenyl l 3-dimethylaminopropyl )-6- methyl-l-H-pyrrolol l .2,3-de]quinoxalin-2(3H)-one.

23. A compound as described in claim 1 which is: 5- (m-chlorophenyl l 3-dimethylaminopropyl )-6- methyl- 1 H-pyrrolo[ l ,2,3-de]quinoxalin-2( 3H)-one.

24. A compound as described in claim 1 which is: 5- (p-chlorophenyl)-l-(3-dimethylaminopropyl)-6- methyl- 1 H-pyrrolo[ l ,2,3-de]quinoxalin-2( 3H )-one.

25. A compound as described in claim 1 which is: l- (3-dimethylaminopropyl)-5-(p-hydroxyphenyl)-6 

1. A COMPOUND SELECTED FROM THE GROUP CONSISTING OF: . 3-(3-DIMETHYLAMINOPROPYL)-8,9,10,11-TETRAHYDRO1H,7H -CYCLOHEPTAL(4,5)PYRROLO(1,2,3-DE)QUINOXALIN2(3H)-ONE. B. 3-(2-DIMRTHYLAMINOETHYL)-8,9,10,11-TETRAHYDRO -1H,7HCYCLOHEPTA(4,5)PYRROLO(1,2,3-DE)QUINOXALIN-2(3H)-ONE. C. 6-METHYL-1-(2-DIMETHYLAMINOETHYL)-5-PHENYL-1H-PYRROLO1,2,3-DE)QUINOXALIN -2(3H)-ONE. D. 1-(3-DIMETHYLAMINOPROPYL)-5-METHYL-6-PHENYL-1H-PYRROLO(1,2,3-DE)QUINOXALIN -2(3H)-ONE. E. 3-(2-DIMETHYLAMINOETHYL)-7,8,9,10,11,12-HEXAHYDRO1H -CYCLOOCTA74,5)PYRROLO(1,2,3-DE)QUINOXALIN2(3H)-ONE. F. 3-(3-DIMETHYLAMINOPROPYL)-8,9-DIHYDRO-1H,7HCYCLOPENTAL(4,5)PYRROLO(1,2,3 -DE)QUINOXALIN-2(3H)-ONE G. 5-BENZYL-1-(2-DIMETHYLAMINOETHYL)-6-PHENYL-1H-PYRROLO(1,2,3-DE)QUINOXALIN -2(3H)-ONE. H. 1-(3-DMETHYLAMINO-2-METHYLPROPYL)-6-ETHYL-5-PHENYL1H-PYRROLO(1,2,3 -DE)QUINOXALIN-2(3H)-ONE. I. 1-(3DIMETHYLAMINO-1-METHYLPROPYL)-6-ETHYL-5-PHENYL1H-PYRROLO(1,2,3 -DE)QUINOXALIN-2(3H)-ONE J. 1-(2-DIMETHYLAMINOETHYL)-6-ETHYL-5-PHENYL-1H-PYRROLO(1,2,3-DE)QUINOXALIN -2(3H)-ONE. K. 1-(3-DIMETHYLAMINOPROPYL)-6-METHYL-5 PHENYL-1H-PYRROLO(1,2,3-DE)QUINOXALIN-2(3H)-ONE. L. 1-(3-DIMETHYLAMINOPROPYL)-5-PHENYL-6-PROPYL - 1H - PYRROLO(1,2,3-DE)QUINOXALIN-2(3H)ONE. M. 1-(3-DIMETHYLAMINOPROPYL)-6-ETHYL-5-METHYL-1H-PYRROLO(1,2,3-DE)QUINOXALIN -2(3H)-ONE. N. 6-ETHYL-1-(2-MORPHOLINOETHYL)-5-PHENYL-1H-PYRROLO(1,2,3-DE)QUINOXALIN-2(3H)--ONE. O. 1-(2-DIETHYLAMINOETHYL)-6-ETHYL-5-PHENYL-1H-PYRROLO(1,2,3-DE)QYUINOXALIN -2(3H)-ONE. P. 6-ETHYL-1-(-MORPHOLINOPROPYL)-5-PHENYL-1H-PYRROLO(1,2,3-DE)QUINOXALIN-2(3H) -ONE. Q. 6-ETHYL-5-PHENYL-1-(2-(1-PYRROLIDINYL)ETHYL)1H-PYRROLO(1,2,3-DE)QUINOLIN -2(3H)-ONE. R. 6-ETHYL-1-(3-METHYLAMINOPROPYL)-5-PHENYL-1H-PYRROLO(1,2,3-DE)QUINOXALIN -2(3H)-ONE. S. 6-ETHYL-5-PHENYL-1-(3-(1-PYRROLIDINYL)PROPYL)-1H-PYRROLO(1,2,3-DE)QUINOXALIN-2(3H)-ONE. T. 1-(3-DIMETHYLAMINOPROPYL)-5(P-METHOXYPHENYL)-6METHYL-1H-PYRROLO(1,2,3 -DE)QUINOLIN-2(3H)-ONE. U. 5-(P-BENZYLOXYPHENYL)-1-)3-DIMETHYLAMINOPROPYL)-6METHYL-1H-PYRROLO(1,2,3 -DE)QUINOXALIN-2(3H)-ONE. V. 5-(M-CHLOROPHENYL)-1-(3-DIMETHYLAMINOPROPYL)-6METHYL-1H-PYRROLO(1,2,3 -DE)QUINOXALIN-2(3H)-ONE. W. 5-(P-CHLOROPHENYL)-(3-DIMETHYLAMINOPROPYL)-6METHYL-1H-PYRROLO(1,2,3 -DE)QUINXALIN-2(3H)-ONE. X. 1-(3-DIMETHYLAMINOPROPYL)-5-(P-HYDROXYPHENYL)-6METHYL-1H-PYRROLO(1,2,3 -DE)QUINOXALIN-2(OH)ONE. Y. 1-(3-DIMETHYLAMINOPROPYL)-5-PHENYL-1H-PYRROLO(1,2,3DE)QUINOXALIN-2(3H)-ONE. Z. 5-(O-CHLOROPHENYL)-1-(3-DIMETHYLAMINOPROPYL)-6-METHYL-1H-PYRROLO(1,2,3 -DE)QUINOXALIN-2(3H)-ONE. AA. 7,8,9,10-TETRAHYDRO-8-METHYL-1H-PYRIDO(3,4,:4,5)PYRROLO(1,2,3-DE)QUINOXALIN -2(3H)-ONE.
 2. A compound as described in claim 1 which is: 3-(3-dimethylaminopropyl)-8,9,10,11-tetrahydro-1H,7H-cyclohepta(4, 5)pyrrolo(1,2,3-de)quinoxalin-2(3H)-one.
 3. A compound as described in claim 1 which is: 3-(2-dimethylaminoethyl)-8,9,10,11-tetrahydro-1H,7H-cyclohepta(4, 5)pyrrolo(1,2,3-de)quinoxalin-2(3H)-one.
 4. A compound as described in claim 1 which is: 6-methyl-1-(2-dimethylaminoethyl)-5-phenyl-1H-pyrrolo(1,2,3-de)quinoxalin -2(3H)-one.
 5. A compound as described in claim 1 which is: 1-(3-dimethylaminopropyl)-5-methyl-6-phenyl-1H-pyrrolo(1,2,3-de)quinoxalin -2(3H)-one.
 6. A compound as described in claim 1 which is: 3-(2-dimethylaminoethyl)-7,8,9,10,11,12-hexahydro-1H-cycloocta(4, 5)pyrrolo(1,2,3-de)quinoxalin-2(3H)-one.
 7. A compound as described in claim 1 which is: 3-(3-dimethylaminopropyl)-8,9-dihydro-1H,7H-cyclopenta(4,5)pyrrolo(1, 2,3-de)quinoxalin-2(3H)-one.
 8. A compound as described in claim 1 which is: 5-benzyl-1-(2-dimethylaminoethyl)-6-phenyl-1H-pyrrolo(1,2,3-de)quinoxalin -2(3H)-one.
 9. A compound as described in claim 1 which is: 1-(3-dimethylamino-2-methylpropyl)-6-ethyl-5-phenyl-1H-pyrrolo(1,2,3 -de)quinoxalin-2(3H)-one.
 10. A compound as described in claim 1 which is: 1-(3-dimethylamino-1-methylpropyl)-6-ethyl-5-phenyl-1H-pyrrolo(1,2,3 -de)quinoxalin-2(3H)-one.
 11. A compound as described in claim 1 which is: 1-(2-dimethylaminoethyl)-6-ethyl-5-phenyl-1H-pyrrolo(1,2,3-de)quinoxalin -2(3H)-one.
 12. A compound as described in claim 1 which is: 1-(3-dimethylaminopropyl)-6-methyl-5-phenyl-1H-pyrrolo(1,2,3-de)quinoxalin -2(3H)-one.
 13. A compound as described in claim 1 which is: 1-(3-dimethylaminopropyl)-5-phenyl-6-propyl-1H-pyrrolo(1,2,3-de)quinoxalin -2(3H)-one.
 14. A compound as described in claim 1 which is: 1-(3-dimethylaminopropyl)-6-ethyl-5-methyl-1H-pyrrolo(1,2,3-de)quinoxalin -2(3H)-one.
 15. A compound as described in claim 1 which is: 6-ethyl-1-(2-morpholinoethyl)-5-phenyl-1H-pyrrolo(1,2,3-de)quinoxalin-2(3H) -one.
 16. A compound as described in claim 1 which is: 1-(2-diethylaminoethyl)-6-ethyl-5-phenyl-1H-pyrrolo(1,2,3-de)quinoxalin -2(3H)-one.
 17. A compound as described in claim 1 which is: 6-ethyl-1-(3-morpholinopropyl)-5-phenyl-1H-pyrrolo(1,2,3-de)quinoxalin-2(3H)-one.
 18. A compound as described in claim 1 which is: 6-ethyl-5-phenyl-1-(2-(1-pyrrolidinyl)ethyl)-1H-pyrrolo(1,2,3-de)quinoxalin -2(3H)-one.
 19. A compound as described in claim 1 which is: 6-ethyl-1-(3-methylaminopropyl)-5-phenyl-1H-pyrrolo(1,2,3-de)quinoxalin -2(3H)-one.
 20. A coMpound as described in claim 1 which is: 6-ethyl-5-phenyl-1-(3-(1-pyrrolidinyl)propyl)-1H-pyrrolo(1,2,3-de)quinoxalin-2(3H)-one.
 21. A compound as described in claim 1 which is: 1-(3-dimethylaminopropyl)-5-(p-methoxyphenyl)-6-methyl-1H-pyrrolo(1,2, 3-de)quinoxalin-2(3H)-one.
 22. A compound as described in claim 1 which is: 5-(p-benxyloxyphenyl)-1-(3-dimethylaminopropyl)-6-methyl-1-H-pyrrolo(1,2,3 -de)quinoxalin-2(3H)-one.
 23. A compound as described in claim 1 which is: 5-(m-chlorophenyl)-1-(3-dimethylaminopropyl)-6-methyl-1H-pyrrolo(1,2, 3-de)quinoxalin-2(3H)-one.
 24. A compound as described in claim 1 which is: 5-(p-chlorophenyl)-1-(3-dimethylaminopropyl)-6-methyl-1H-pyrrolo(1,2, 3-de)quinoxalin-2(3H)-one.
 25. A compound as described in claim 1 which is: 1-(3-dimethylaminopropyl)-5-(p-hydroxyphenyl)-6-methyl-1H-pyrrolo(1,2, 3-de)quinoxalin-2(3H)-one.
 26. A compound as described in claim 1 which is: 1-(3-dimethylaminopropyl)-5-phenyl-1H-pyrrolo(1,2,3-de)quinoxalin-2(3H)-one.
 27. A compound as described in claim 1 which is: 5-(o-chlorophenyl)-1-(3-dimethylaminopropyl)-6-methyl-1H-pyrrolo(1,2, 3-de)quinoxalin-2(3H)-one.
 28. 7,8,9,10-tetrahydro-8-methyl-1H-pyrido(3'',4'':4,5)pyrrolo(1, 2,3-de)quinoxalin-2(3H)-one. 